Liang, Kai Ling http://orcid.org/0000-0002-8534-2362
Roels, Juliette http://orcid.org/0000-0001-7230-3690
Lavaert, Marieke
Putteman, Tom
Boehme, Lena http://orcid.org/0000-0001-7593-7533
Tilleman, Laurentijn http://orcid.org/0000-0001-7584-1179
Velghe, Imke
Pegoretti, Valentina
Van de Walle, Inge http://orcid.org/0000-0002-7631-399X
Sontag, Stephanie
Vandewalle, Jolien http://orcid.org/0000-0003-1844-6476
Vandekerckhove, Bart
Leclercq, Georges http://orcid.org/0000-0002-1691-5294
Van Vlierberghe, Pieter http://orcid.org/0000-0001-9063-7205
Libert, Claude
Van Nieuwerburgh, Filip http://orcid.org/0000-0001-8815-5485
Fischer, Roman
Kontermann, Roland E.
Pfizenmaier, Klaus
Doody, Gina
Zenke, Martin
Taghon, Tom http://orcid.org/0000-0002-5781-0288
Article History
Received: 20 October 2021
Accepted: 16 December 2022
First Online: 26 January 2023
Competing interests
: K.L.L. and T.T. filed a PCT application (PCT/EP2022/063712: Generating T cell precursors via agonizing tumor necrosis factor receptor 2) with the European Patent Office on 20th May 2022. K.P., R.F. and R.E.K. are named inventors on a patent covering the TNFR2-specific agonist (EZH2-scTNF<sub>R2</sub>). R.F. and R.E.K. received funding from Resano, a company that has licensed the technology to generate TNFR2-specific agonist. R.E.K. is a consultant for Immatics, Oncomatryx, Roche and SunRock. K.P. is a consultant for Oncomatryx, Resano and SunRock. The remaining authors declare no competing interests.